Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· July 3, 2026

Bull of the Day: Bloom Energy (BE)

View original at nasdaq.com
Bull of the Day: Bloom Energy (BE) I have written about Bloom Energy (BE) several times recently as the Bull of the Day…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bloom's ability to provide reliable, dispatchable power to a volatile demand profile differentiates it from competitors.

    60% confidence
  • Brookfield took its Bloom Energy commitment from $5B to $25B in eight months, a fivefold increase; this is the 'Electrons to Tokens' trade, with a trillion-dollar allocator buying the behind-the-meter watt as the fifth straight deal into the same name.

    60% confidence
  • The Bloom box is intended to replace the grid for its customers, being cheaper and cleaner than the grid.

    60% confidence
  • Scaling the Bloom Energy commitment reflects the strength of the partnership and Brookfield's broader AI infrastructure strategy, positioning Brookfield as a leading global AI infrastructure investor delivering end-to-end solutions from electrons to tokens.

    60% confidence
  • The expanded partnership reflects strong and sustained demand from hyperscalers and AI infrastructure developers for fast, reliable, and community-friendly power, bringing together Brookfield's global leadership and access to capital with Bloom's rapidly deployable onsite power platform.

    60% confidence
  • Bloom's story is a microcosm of how AI-bearish economists and analysts have missed the fundamental demand drivers.

    60% confidence
  • Five Bloom Boxes on eBay's campus produced five times as much usable, consistent 24/7 electricity as its entire footprint of over 3,200 rooftop solar panels.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com